Combined inhibition of c-Myc and KRAS was effective to abrogate KRASG12Ci resistance and potently enhanced the drug efficacy in NSCLC and PAAD cells with KRASG12C mutation. This evidence concerns the gene MYC and non-small cell lung carcinoma.